Wholeleaf, a licensed pain therapeutics company, has drawn ambitious plan with expansion in Bangalore, Mumbai and Hyderabad before penetrating into other key markets in Kolkata, Ahmedabad, Goa and Chennai by end of this year.

The move is part of the company’s plan to have a pan-India presence. It plans to grow its retail footprint to about 7,000 outlets through tie-ups with mom-and-pop pharmacy stores and large retail chains such as Apollo Pharmacy, Wellness Forever, and Guardian.

Wholeleaf is one of the fastest-growing early-licensed and compliant entrants in India’s cannabinoid-based therapeutics segment.

The company’s early investments in compliance, clinical trials and approvals have shaped its long-term approach as licensed and evidence based therapeutics company.

With a growing portfolio of oral and topical formulations, the company addresses a wide spectrum of chronic pain conditions, including migraines, arthritis, fibromyalgia, menstrual pain and neuralgia.

Building on this foundation, it is now developing a pipeline of innovative solutions for chronic neuropathic pain—an area that continues to pose significant challenges for patients and clinicians alike.

Wholeleaf also follows a stringent and structured product development process involving key stakeholders, including physicians and pharmacologists. Its formulations are tested through third-party, government-certified laboratories to further ensure compliance and safety standards.

The proposed expansion strategy comes at a time when cannabinoid-based therapeutics in India are transitioning from a niche, low-awareness segment into a high-growth emerging category, with estimated growth of 20–25 per cent CAGR.

Increasing global clinical validation of cannabinoid-based therapies, coupled with the rising prevalence of lifestyle-driven conditions such as chronic pain, anxiety, and insomnia, is accelerating demand for such solutions.

Shivraj Sharma, Founder and CEO, Wholeleaf, expects strong growth in the cannabinoid-based therapeutics industry in India, driven by the increasing burden of chronic conditions and a clear need for safer, sustainable pain management solutions.

“Our expansion is focused on improving accessibility through trusted retail and medical channels, while simultaneously strengthening our digital presence to expand reach,” he said.

Published on May 23, 2026